罗氟司特国内哪里有卖的？

Inflammation is the core of the pathogenesis of chronic obstructive pulmonary disease (COPD). Anti-inflammatory treatment plays an important role in the management of COPD. Phosphodiesterase 4 (PDE4) is expressed in inflammatory cells and smooth muscle cells and is the target of anti-inflammatory treatment. PDE4 inhibitors can effectively antagonize airway inflammation. Roflumilast is a long-acting inhibitor of selective phosphodiesterase type 4 (PDE-4) and has a wide range of anti-inflammatory activities including inhibiting the release of inflammatory mediators and inhibiting immune cell activation.

Roflumilast is the first oral COPD treatment drug and has been highly anticipated since its launch. Where can roflumilast be sold in China?

As of 2021, roflumilast has not been approved for marketing in China. Patients in need can choose roflumilast marketed abroad. For specific drug information, drug prices and how to purchase, patients can contact the medical companion travel service for detailed consultation.

Roflumilast is a phosphodiesterase IV inhibitor that was first approved by the EMA in 2010 as an add-on therapy to the treatment of bronchiectasis for the maintenance treatment of severe COPD in adult patients with chronic bronchitis who have a history of frequent exacerbations. In 2010, Nycomed reached an agreement with Merck to jointly promote roflumilast for the treatment of COPD in Canada and Europe (France, Germany, Italy, Spain and Portugal). Roflumilast was approved by the FDA in March 2011 and launched in the United States in June of that year.

More than 3,000 patients with chronic obstructive pulmonary disease (COPD) were included in two pivotal placebo-controlled clinical studies. Studies have shown that roflumilast can significantly improve patients with moderate to severe exacerbations and prediastolic FEV1, regardless of whether it is combined with a long-acting β2 agonist. The study also demonstrated that roflumilast significantly improved patients' lung function compared with placebo.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended hot articles: